News and Trends 26 Jan 2023
First patient treated in Atrogi type 2 diabetes clinical study
Atrogi AB, an early-stage Swedish pharma company, has announced that the first patient has been enrolled in a phase 1a/b study. Atrogi’s drug candidate, ATR-258 is a first in class…